> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel to Review Ciprofloxacin Dispersion for Inhalation NDA
- URL: https://www.fdaweb.com/panel-to-review-ciprofloxacin-dispersion-for-inhalation-nda/
- Published: 2017-12-01T12:00:00.000Z
- Updated: 2026-09-14T23:04:34.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5140246

*Federal Register* notice: FDA has announced a 1/11/2018 Antimicrobial Drugs Advisory Committee meeting. Panel members are expected to discuss an Aradigm Corp. NDA for ciprofloxacin dispersion for inhalation, indicated for treating non-cystic fibrosis bronchiectasis patients with chronic lung infections with *Pseudomonas aeruginosa*. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-12-01/pdf/2017-25911.pdf?ref=fdaweb.com).